PhD , Chief Executive Officer
Promethera Biosciences appointed Dr John Tchelingerian as its Chief Executive Officer in September, 2015. He initially joined the company as Chairman of the Board end of 2014, and acted as its interim CEO since January, 2015 and up to September, 2015. With the appointment of a new Chairman of the Board in June 2016, John now focusses entirely on his role of CEO, in combination with his Board duties as Series A representative Director.
Dr John Tchelingerian is a serial entrepreneur and a private investor. His background includes strong scientific, business, managerial and deal making experience. He has co-founded and managed several biotech companies including Neurotech (pioneer in cell therapy for central nervous system/retina), Key-Obs, Diatos, TcLand Expression, Key Neurosciences and Melkin Pharmaceuticals. He has raised over $100 million (€81 million) for his entrepreneurial ventures from VCs and private equity sources in Europe, the US and Japan. He has also closed several biotech and pharma partnering deals. Under his leadership, four drugs were developed from the research stage up to clinical phase IIb/III as well as DaunoXome, the marketed drug, was re-launched in a cancer orphan indication both in the USA and the EU, based on phase III clinical trials.
John co-founded Silver Ocean Ventures, a strategic advisory and corporate finance firm, in 2009 based in Paris. It primarily services the global life sciences industry regarding corporate finance, strategic business transactions and active board and leadership roles. John has been responsible for Silver Ocean Ventures closing several international capital raising and M&A transactions with a total value of over €50 million. As a scientist, John is inventor in several patents in the field of cell therapy and drug delivery. He is a PhD graduate in Neurosciences from Pierre et Marie Curie University in Paris, France. He is fluent in five languages.